Drug Coated Balloons in Femoropopliteal Territory: Predictors of Failed Patency

Endovascular treatment in femoropopliteal territory has become the strategy of choice over time, with diverse devices; among others, drug coated balloons (DCB). DBS are meant to provide the antiproliferation effect of drugs while reducing exposure of a specific artery segment to a strange body.  

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

Even though the number of studies on DCB effectiveness has been growing over the years, there are few data on the mechanisms behind DCB failure. 

The aim of this study was to look into clinical characteristics, anatomical factors and procedural variables related to DCB failure in femoropopliteal territory.

Data pooled from several studies using Paclitaxel IN.PACT Admiral DCB (among others, the IN.PACT SFA, MDT-2113 and the IN.PACT Global) were looked at retrospectively, which left them out with a population from 83 sites in 17 countries. 

Primary end point was primary patency loss (freedom form clinically driven target lesion revascularization (TLR), and freedom from binary stenosis) during a 12-month followup. 

Data from 557 patients were obtained, with single lesions treated with IN.PACT Admiral DCB, mean age was 70, 67.5% were men, 87% were hypertensive, 40.5% diabetic and 38.2% were smokers. 46% of cases presented prior peripheral intervention, and most were in Rutherford class II (33%) and III (57.2%).  

Read also: Left Atrial Appendage Closure Is a Valid Option.

After 12 months, primary patency loss was 17.5%, binary restenosis 15.6% and clinically driven TLR 5.3%. Multivariable analysis of variables associated with patency loss at followup were residual stenosis >30% (HR: 2.94, CI 95%: 1.76-4.92; P<0.001). 

The presence of residual stenosis associated to a reference diameter of the reduced vessel was linked to a 57% increase in binary restenosis (HR: 1.57, CI 95% 1.01-2.46; P=0.046). Patients with residual stenosis in Rutherford class III presented higher risk of clinically driven TLR (HR 4.19, IC 95% 1.68-10.46; P=0.002). 

Conclusions

This analysis of patients pooled from studies using the IN.PACT Admiral DCB showed some factors that can predict patency failure at 12 months. Those with the highest impact were residual stenosis >30% after procedure, smaller reference diameter, and Rutherford class III.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.

Reference: Krishnan, Prakash et al. “Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention.” Journal of the American College of Cardiology vol. 80,13 (2022): 1241-1250. doi:10.1016/j.jacc.2022.06.043.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

Atherosclerotic Renal Artery Stenosis: To Revascularize or Not

At long term, atherosclerotic renal artery stenosis (RAS) can lead to hypertension, chronic kidney disease, and cardiac failure. Historically, these patients have been referred...

Endovascular Management of Chronic TEPH: Is Coronary Management Extrapolatable in This Scenario?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition that causes significant functional limitation. Its surgical treatment, known as pulmonary endarterectomy (PEA), has improved the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...